NO20065084L - Interferon-alfa polypeptider og konjugater - Google Patents

Interferon-alfa polypeptider og konjugater

Info

Publication number
NO20065084L
NO20065084L NO20065084A NO20065084A NO20065084L NO 20065084 L NO20065084 L NO 20065084L NO 20065084 A NO20065084 A NO 20065084A NO 20065084 A NO20065084 A NO 20065084A NO 20065084 L NO20065084 L NO 20065084L
Authority
NO
Norway
Prior art keywords
conjugates
polypeptides
nucleic acids
interferon
alpha polypeptides
Prior art date
Application number
NO20065084A
Other languages
English (en)
Inventor
Adelbert Grossmann
Stephan Fischer
Ralf Schumacher
Torben Lauesgaard Nissen
Phillip A Patten
Sridhar Viswanathan
Anne Vogt
Harald Kropshofer
Stefan Seeber
Friederike Hesse
Andreas Schaubmar
Roberto Falkenstein
Hans Koll
Markus Dembowski
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of NO20065084L publication Critical patent/NO20065084L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer interferon-alfa-polypeptider og konjugater, samt nukleinsyrer som koder for polypeptidene. Oppfinnelsen omfatter også sammensetninger omfattende disse polypeptidene, konjugatene og nukleinsyrene; celler inneholdende eller som uttrykker polypeptidene, konjugatene og nukleinsyrene; fremgangsmåter for fremstilling av polypeptidene, konjugatene og nukleinsyrene; og fremgangsmåter for anvendelse av polypeptidene, konjugatene og nukleinsyrene.
NO20065084A 2004-05-19 2006-11-03 Interferon-alfa polypeptider og konjugater NO20065084L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
NO20065084L true NO20065084L (no) 2006-12-01

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065084A NO20065084L (no) 2004-05-19 2006-11-03 Interferon-alfa polypeptider og konjugater

Country Status (14)

Country Link
US (9) US7318918B2 (no)
EP (1) EP1753779A2 (no)
JP (1) JP2008507298A (no)
CN (1) CN101115769A (no)
AR (1) AR049177A1 (no)
AU (1) AU2005245918A1 (no)
BR (1) BRPI0511196A (no)
CA (1) CA2566247A1 (no)
IL (1) IL178470A0 (no)
MX (1) MXPA06013412A (no)
NO (1) NO20065084L (no)
RU (1) RU2006145020A (no)
TW (1) TW200611910A (no)
WO (1) WO2005113592A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042730D1 (de) 1999-01-05 2009-09-24 Univ Boston Verbessertes klonierungsverfahren
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
KR20070038462A (ko) * 2004-05-12 2007-04-10 퓨전원 인코포레이티드 향상된 접속 인식 시스템
ATE540110T1 (de) 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008008808A2 (en) * 2006-07-11 2008-01-17 Modular Genetics Inc. Methods of introducing targeted diversity into nucleic acid molecules
WO2008013082A1 (fr) * 2006-07-25 2008-01-31 Galpharma Co., Ltd. Conjugué galectine 9/polymère
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
TWI544930B (zh) * 2007-10-01 2016-08-11 藥華醫藥股份有限公司 Ｎ端修飾之干擾素－α
CA2711375C (en) * 2008-01-18 2019-04-16 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
CN102281903B (zh) * 2008-11-17 2013-11-13 弗·哈夫曼-拉罗切有限公司 降低大分子在生理条件下聚集的方法和配方
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
AR086659A1 (es) * 2011-06-02 2014-01-15 Hanmi Science Co Ltd Multimero de insulina-polimero no peptidilo y metodo para su produccion
WO2013003555A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
BR112022014567A2 (pt) * 2020-01-24 2022-09-27 Alkermes Pharma Ireland Ltd Métodos de purificação

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ES2128348T3 (es) 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
BR122013003013B8 (pt) 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
WO2000052153A2 (en) * 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
BR0010725A (pt) 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CN1451045A (zh) * 1999-10-07 2003-10-22 马克西根公司 IFN－α同系物
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
CA2503594C (en) 2002-11-15 2011-05-10 Doris Brugger Positional isomers of peg ifn alpha 2a
WO2004046365A2 (en) 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
US20070225205A1 (en) 2007-09-27
US20070225204A1 (en) 2007-09-27
AR049177A1 (es) 2006-07-05
WO2005113592A3 (en) 2006-04-06
US7318918B2 (en) 2008-01-15
CN101115769A (zh) 2008-01-30
US20080076710A1 (en) 2008-03-27
TW200611910A (en) 2006-04-16
US20080171363A1 (en) 2008-07-17
AU2005245918A1 (en) 2005-12-01
RU2006145020A (ru) 2008-06-27
US7541436B2 (en) 2009-06-02
US7537755B2 (en) 2009-05-26
US20050266465A1 (en) 2005-12-01
BRPI0511196A (pt) 2007-12-04
US20070020235A1 (en) 2007-01-25
IL178470A0 (en) 2007-02-11
US20070020734A1 (en) 2007-01-25
US20070025966A1 (en) 2007-02-01
JP2008507298A (ja) 2008-03-13
EP1753779A2 (en) 2007-02-21
CA2566247A1 (en) 2005-12-01
US7531630B2 (en) 2009-05-12
US7541163B2 (en) 2009-06-02
WO2005113592A2 (en) 2005-12-01
MXPA06013412A (es) 2007-01-23
US7531324B2 (en) 2009-05-12
US20080031853A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
NO20065084L (no) Interferon-alfa polypeptider og konjugater
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
HK1210627A1 (en) Preparing crude biological estracts using protease, suitable for preparing cdna cdna
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
WO2006017538A3 (en) Hk1-binding proteins
DK1641910T3 (da) Glucanaser, nucleinsyrer, som koder for disse, og fremgangsmåder til at fremstille og benytte disse
DK1516053T3 (da) Xylanaser, nucleinsyrer, som koder herfor, og fremgangsmåder til at fremstille og benytte disse
WO2006066024A8 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2004061080A3 (en) Stress-related polypeptides and uses therefor
NO20072966L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse
WO2005103229A3 (en) Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using
WO2004007664A3 (en) Nucleic acid vectors
WO2006039396A3 (en) Non-embedded tissue microarray technology for protein and nucleic acid analyses
WO2006063028A3 (en) Immunostimulatory compositions and uses thereof
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses